YILIMART - CD90-MicroBeads, human

The CD90 MicroBeads, human were developed for the positive selection or depletion of cells expressing human CD90 antigen, e.g., liver cancer stem cells from single cell suspensions from solid tumors or cancer cell lines.

Background information

The CD90 antibody reacts with the human CD90 antigen, also known as Thy-1. CD90 was identified as a marker for cancer stem cells in human liver cancer

¹

. In addition to cancer stem cells, it is expressed on embryonic stem cells (ESC), induced pluripotent stem cells (iPSC), neurons, small subsets of human fetal liver cells and thymocytes, cord blood and bone marrow cells. CD90 is also expressed on a subset of CD34

⁺

primitive hematopoietic stem cells. CD90

⁺

CD34

⁺

cells characterize a highly enriched population of high proliferative potential colony-forming cells (HPP-CFC)

²

. Furthermore, CD90 expression is found on mesenchymal stem cells (MSCs)

³

.

Columns

For positive selection: MS, LS, or autoMACS

^®

Columns. For depletion: LD or autoMACS Columns.

Figure 1

Unseparated fraction	CD90 ⁺ cells

Selected references
1. Zhen Fan Yang, Z. F. et al. (2008)
  
  Significance of CD90
  ⁺
  cancer stem cells in human liver cancer.
  
  Cancer Cell 13: 153-166
2. Mayani, H. and Lansdorp, P. M. (1994) Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 83: 2410-2417
3. Dominici, M. et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317
Brochures and posters

Cancer Research

查看数据文件查看下载

CD90-MicroBeads, human

For research use only

您浏览过的商品

Background information

Columns

Figure 1

Selected references

Brochures and posters

相关产品